156 related articles for article (PubMed ID: 18038971)
1. Nuclear magnetic resonance fragment-based identification of novel FKBP12 inhibitors.
Stebbins JL; Zhang Z; Chen J; Wu B; Emdadi A; Williams ME; Cashman J; Pellecchia M
J Med Chem; 2007 Dec; 50(26):6607-17. PubMed ID: 18038971
[TBL] [Abstract][Full Text] [Related]
2. Structure-based design of novel, urea-containing FKBP12 inhibitors.
Dragovich PS; Barker JE; French J; Imbacuan M; Kalish VJ; Kissinger CR; Knighton DR; Lewis CT; Moomaw EW; Parge HE; Pelletier LA; Prins TJ; Showalter RE; Tatlock JH; Tucker KD; Villafranca JE
J Med Chem; 1996 Apr; 39(9):1872-84. PubMed ID: 8627611
[TBL] [Abstract][Full Text] [Related]
3. Differential responses of the backbone and side-chain conformational dynamics in FKBP12 upon binding the transition-state analog FK506: implications for transition-state stabilization and target protein recognition.
Brath U; Akke M
J Mol Biol; 2009 Mar; 387(1):233-44. PubMed ID: 19361439
[TBL] [Abstract][Full Text] [Related]
4. FK506-binding protein ligands: structure-based design, synthesis, and neurotrophic/neuroprotective properties of substituted 5,5-dimethyl-2-(4-thiazolidine)carboxylates.
Zhao L; Huang W; Liu H; Wang L; Zhong W; Xiao J; Hu Y; Li S
J Med Chem; 2006 Jul; 49(14):4059-71. PubMed ID: 16821768
[TBL] [Abstract][Full Text] [Related]
5. Intraligand hydrophobic interactions rationalize drug affinities for peptidyl-prolyl cis-trans isomerase protein.
Bizzarri M; Marsili S; Procacci P
J Phys Chem B; 2011 May; 115(19):6193-201. PubMed ID: 21500789
[TBL] [Abstract][Full Text] [Related]
6. Establishment of a cell model based on FKBP12 dimerization for screening of FK506-like neurotrophic small molecular compounds.
Xiao H; Wang LL; Shu CL; Yu M; Li S; Shen BF; Li Y
J Biomol Screen; 2006 Apr; 11(3):225-35. PubMed ID: 16490780
[TBL] [Abstract][Full Text] [Related]
7. Wheat FKBP73 functions in vitro as a molecular chaperone independently of its peptidyl prolyl cis-trans isomerase activity.
Kurek I; Pirkl F; Fischer E; Buchner J; Breiman A
Planta; 2002 May; 215(1):119-26. PubMed ID: 12012248
[TBL] [Abstract][Full Text] [Related]
8. Insertion of a chaperone domain converts FKBP12 into a powerful catalyst of protein folding.
Knappe TA; Eckert B; Schaarschmidt P; Scholz C; Schmid FX
J Mol Biol; 2007 May; 368(5):1458-68. PubMed ID: 17397867
[TBL] [Abstract][Full Text] [Related]
9. FKBP family proteins: immunophilins with versatile biological functions.
Kang CB; Hong Y; Dhe-Paganon S; Yoon HS
Neurosignals; 2008; 16(4):318-25. PubMed ID: 18635947
[TBL] [Abstract][Full Text] [Related]
10. A library of fluorescent peptides for exploring the substrate specificities of prolyl isomerases.
Zoldák G; Aumüller T; Lücke C; Hritz J; Oostenbrink C; Fischer G; Schmid FX
Biochemistry; 2009 Nov; 48(43):10423-36. PubMed ID: 19785464
[TBL] [Abstract][Full Text] [Related]
11. Peptidyl-prolyl isomerase activity of FK506 binding protein 12 prevents tau peptide from aggregating.
Ikura T; Ito N
Protein Eng Des Sel; 2013 Sep; 26(9):539-46. PubMed ID: 23832849
[TBL] [Abstract][Full Text] [Related]
12. Comparative analysis of calcineurin inhibition by complexes of immunosuppressive drugs with human FK506 binding proteins.
Weiwad M; Edlich F; Kilka S; Erdmann F; Jarczowski F; Dorn M; Moutty MC; Fischer G
Biochemistry; 2006 Dec; 45(51):15776-84. PubMed ID: 17176100
[TBL] [Abstract][Full Text] [Related]
13. Reduction of nonspecific binding proteins to self-assembled monolayer on gold surface.
Furuya M; Haramura M; Tanaka A
Bioorg Med Chem; 2006 Jan; 14(2):537-43. PubMed ID: 16314102
[TBL] [Abstract][Full Text] [Related]
14. Investigations of neurotrophic inhibitors of FK506 binding protein via Monte Carlo simulations.
Lamb ML; Jorgensen WL
J Med Chem; 1998 Oct; 41(21):3928-39. PubMed ID: 9767630
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of ketone analogues of prolyl and pipecolyl ester FKBP12 ligands.
Wu YQ; Wilkinson DE; Limburg D; Li JH; Sauer H; Ross D; Liang S; Spicer D; Valentine H; Fuller M; Guo H; Howorth P; Soni R; Chen Y; Steiner JP; Hamilton GS
J Med Chem; 2002 Aug; 45(16):3558-68. PubMed ID: 12139467
[TBL] [Abstract][Full Text] [Related]
16. Peptidyl-prolyl isomerase inhibitors.
Wang XJ; Etzkorn FA
Biopolymers; 2006; 84(2):125-46. PubMed ID: 16302169
[TBL] [Abstract][Full Text] [Related]
17. A peptidyl-prolyl isomerase, FKBP12, accumulates in Alzheimer neurofibrillary tangles.
Sugata H; Matsuo K; Nakagawa T; Takahashi M; Mukai H; Ono Y; Maeda K; Akiyama H; Kawamata T
Neurosci Lett; 2009 Aug; 459(2):96-9. PubMed ID: 19414059
[TBL] [Abstract][Full Text] [Related]
18. Multi-timescale dynamics study of FKBP12 along the rapamycin-mTOR binding coordinate.
Sapienza PJ; Mauldin RV; Lee AL
J Mol Biol; 2011 Jan; 405(2):378-94. PubMed ID: 21073880
[TBL] [Abstract][Full Text] [Related]
19. Dynamics of Aromatic Side Chains in the Active Site of FKBP12.
Weininger U; Modig K; Geitner AJ; Schmidpeter PA; Koch JR; Akke M
Biochemistry; 2017 Jan; 56(1):334-343. PubMed ID: 27936610
[TBL] [Abstract][Full Text] [Related]
20. Pose scoring by NMR.
Wang B; Raha K; Merz KM
J Am Chem Soc; 2004 Sep; 126(37):11430-1. PubMed ID: 15366876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
